HELPNasdaqPharmaceutical PreparationsFiscal year ends March 31
Helus Pharma Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 40-F on Jun 29, 2026
$10.69+0.14 (+1.33%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Mar 31, 2022 | Jun 22, 2022 | Before market open | – | – | – |
Press releases
Announcements Helus Pharma filed with the SEC
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
EX-99.1 to Form 6-K
Helus Pharma to Host Investor Presentation on October 21, 2026
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Item 1. Name and Address of Company
EX-99.1 to Form 6-K
Helus Pharma Announces Completion of Legal Name Change
EX-99.1 to Form 6-K
SECTION 11.3 OF NATIONAL INSTRUMENT 51-102
EX-99.2 to Form 6-K
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
CYBIN INC. DOING BUSINESS AS HELUS PHARMA
EX-99.3 to Form 6-K
CYBIN INC. DOING BUSINESS AS
EX-99.1 to Form 6-K
CYBIN INC. DOING BUSINESS AS
EX-99.2 to Form 6-K
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
EX-99.1 to Form 6-K
Item 1. Name and Address of Company
EX-99.1 to Form 6-K
HELUS PHARMA TM ANNOUNCES CLOSING OF US$50 MILLION UNDERWRITTEN OFFERING
EX-99.1 to Form 6-K
HELUS PHARMA TM ANNOUNCES US$50 MILLION UNDERWRITTEN OFFERING
EX-99.1 to Form 6-K
Helus Pharma Provides Update on APPROACH
EX-99.2 to Form 6-K
As Representatives of the several
EX-99.3 to Form 6-K
Helus Pharma to Participate in the H.C. Wainwright
EX-99.1 to Form 6-K
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
EX-99.1 to Form 6-K
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
EX-99.1 to Form 6-K
Helus Pharma Strengthens Executive Team with Appointment of
EX-99.1 to Form 6-K
Helus Pharma Announces Topline Results in Phase 2 Signal
EX-99.1 to Form 6-K